Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for

Clinical Trial Summary

In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the Investigator's choice of standard therapy with docetaxel or irinotecan. The primary study hypothesis is that treatment with SHR-1210 will prolong overall survival (OS) as compared to treatment with standard therapy.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Not yet recruiting	`NCT05996484` - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma	Phase 2
Recruiting	`NCT02355249` - Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer	Phase 3
Completed	`NCT01691625` - Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer	N/A
Not yet recruiting	`NCT05937438` - Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05777707` - Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma	Phase 1/Phase 2
Recruiting	`NCT02527057` - Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer	N/A
Withdrawn	`NCT00636298` - Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy	Phase 2
Recruiting	`NCT06009705` - Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
Recruiting	`NCT04652180` - Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .	N/A
Recruiting	`NCT04147494` - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues	Early Phase 1
Withdrawn	`NCT03220009` - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Phase 2
Recruiting	`NCT06199895` - Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer	Phase 2
Completed	`NCT00590031` - Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.	Phase 2
Active, not recruiting	`NCT00176800` - Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma	Phase 2
Active, not recruiting	`NCT04607590` - Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
Recruiting	`NCT00991094` - Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Completed	`NCT01855854` - Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH	Phase 2
Not yet recruiting	`NCT06067438` - Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer	Phase 2
Recruiting	`NCT06265285` - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	Phase 2

NCT number	NCT03099382
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact
Status	Completed
Phase	Phase 3
Start date	May 5, 2017
Completion date	May 6, 2019

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms